MedPath

The effects of cabergoline in reducing the size of endometrioma

Phase 3
Recruiting
Conditions
Endometriosis of ovary.
Endometriosis of ovary
Registration Number
IRCT20150817023666N9
Lead Sponsor
Iran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
32
Inclusion Criteria

one-sided endometrioma
Size less than 5 cm
No ultrasound criteria for malignancy
The absence of laboratory criteria for malignancy
Have informed consent to enter the study
Maximum 45 years

Exclusion Criteria

Hormonal treatment includes Contraceptive 3 months before entering the study
Cabergolin sensitivity

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary outcome: 25% reduction in endometrium size. Timepoint: Treatment is done for 12 weeks for intervention and control groups. Method of measurement: The results of ultrasound.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath